- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of Testing for C Difficile in Clinical Practice
Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.
EP: 1.The Role of Testing for C Difficile in Clinical Practice
EP: 2.Utilizing Antibiotics in Treatment of C Difficile
EP: 3.Examining FMT for Patients With Recurrent C Difficile infections
EP: 4.Exploring Rebyota for Recurrent C Difficile Infections
EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
EP: 7.Management of Recurrent C Difficile Infections in the Future
EP: 8.Key Background Information on Recurrent C. Difficile Infections
EP: 9.Importance of Early Detection of Recurrent C Difficile Infections
EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
EP: 11.Diagnosis of Recurrent C Difficile Infections
EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections
EP: 13.Unmet Needs With Recurrent C Difficile Infections
Video content above is prompted by the following:
- In which patients do you test for C difficile before treating?
- Does the timing of the testing influence when you start treatment?
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
